Background: Vaccination is a safe and effective public health intervention that not only protects individual travellers from vaccine-preventable diseases (VPDs), but prevents them from becoming a source of disease in their destination and on their return. Obtaining an accurate vaccination history from travellers during a pre-travel review can be difficult; serology may be used to identify patients who are non-immune to specific diseases in order to guide vaccination requirements. Clinically relevant data about the usefulness of serology in this setting are lacking. We performed a retrospective audit of pre-travel VPD serology requested by practitioners of a busy community-based travel clinic. Methods: All serological results for measles, mumps, rubella, varicella zoster virus, hepatitis A and B requested over a 5-year period were extracted and analysed. Results were stratified by gender and year of birth and compared using Stata. Results: Four thousand four hundred and fifty-one serological assays from 1445 individual were assessed. Overall, 47% of patients tested had at least one negative serological result. High rates of seropositivity for measles, mumps and rubella were seen in those born prior to 1966 but >10% of travellers born after 1966 lacked serological evidence of protection against these diseases. Hepatitis A and B serological results revealed broadly lower rates of immunity in our community likely reflecting the absence of these vaccines from historical vaccine protocols. Conclusions: Serology can be a useful tool in the identification of non-immune travellers to enable targeted vaccination prior to travel. We recommend that travel health clinicians assess patients' vaccination and infection histories, and strongly consider serology or vaccination where there is doubt about immunity. This will help protect the traveller and prevent importation of disease into destination or home communities.
Introduction
Vaccination is a safe and effective public health intervention that reduces the morbidity and mortality caused by vaccinepreventable diseases (VPDs). In high-income countries such as Australia, effective childhood vaccination programmes with high coverage rates ensure that the risk of most VPDs remains low. However, international travel from such countries to areas of higher disease prevalence can place inadequately vaccinated Original Article travellers at risk. Global international tourist arrivals now number 1.2 billion annually, an increase of 375 million in the last 10 years. 1 Australian vaccination guidelines designate international travellers as a special group. 2 Inadequate vaccination not only puts the traveller at risk, but also potentially enables disease transmission among destination communities during travel and among the home community following return. Measles, mumps, rubella (MMR) vaccination is recommended for all travellers without a clear history of two doses of vaccine born after 1966, and varicella zoster virus (VZV) vaccine is recommended in those without a clear history of vaccination or previous infection. Hepatitis A vaccination is recommended for travellers to areas of higher prevalence. Hepatitis B vaccination is recommended for long-term travellers or frequent short-term travellers to areas of high prevalence. When adult patients present for a pre-travel health review it can be difficult to establish an accurate history of past vaccination or past infection with VPDs. In such cases, serological testing for immunity from prior vaccination and/or infection may be useful to guide vaccination requirements for diseases where serology has been shown to correlate with protective immunity. Given the inconvenience and costs of testing, this approach is generally reserved for those in whom there is doubt regarding immunity. We performed a retrospective audit of pre-travel serology in travellers with uncertain prior exposure or vaccination history attending a large travel clinic to determine the utility of targeted screening prior to travel.
Methods
Data were obtained via a de-identified search of the pathology database of a dedicated community-based travel clinic in Melbourne, Australia, staffed by general practitioners. All serum immunoglobulin G (IgG) levels for MMR, VZV, hepatitis A and B performed at initial consultations between January 2011 and December 2015 were extracted and analysed. Serological tests performed at subsequent visits were not included. Serology was performed only in those travellers for whom immunity to one or more of the above VPDs could not be definitively determined following review of the patient's clinical history, previous serology results and vaccination documentation. Commercial assays were used to determine IgG levels. Results were considered negative if IgG titres were not detected or below the pathology laboratory's recommended cut-off for immunity. Data were stratified into three cohorts based on year of birth: born prior to 1966, born 1966-1982 and born after 1982. Cohorts reflect relevant changes in local vaccination practices as summarized in Table 1 . Data were analysed using Stata version 14 (StataCorp, Texas, USA). Univariate analysis was performed to examine the impact of sex and birth year on seronegativity rates for each disease. Logistic regression was used to generate odds ratios (OR) with 95% confidence intervals (95%) and P-values.
Results
One thousand four hundred and forty-five patients had at least one serological test performed, with 4451 individual serological assays included in the analysis. 350 patients (24%) had 1 serological test performed, 337 patients (23%) had 2 tests performed and 758 patients (53%) had 3 or more tests performed. Of those who had 1 test performed, hepatitis B serology (104/ 350; 30%) and VZV serology (99/350; 28%) were the most commonly performed assays. Of those who had two tests performed, 122 patients (57%) had serological testing for both hepatitis A and B. Of those who had three or more tests performed, 492 (65%) had serological testing for MMR. Year of birth ranged from 1925 to 2000 and 54% were female. Overall, 47% of patients had one or more seronegative result. Serological results consistent with non-immunity were demonstrated in 8% of those tested for measles, 12% of those tested for mumps, 8% of those tested for rubella, 24% of those tested for hepatitis A, 53% of those tested for hepatitis B and 11% of those tested for VZV ( Table 2 ). Patients born after 1966 were significantly more likely to be non-immune to measles than those born prior to 1966 (P < 0.001). Mumps showed higher overall levels of non-immunity (16.5% of those born after 1982). Males were 2.55 times more likely to be seronegative for rubella than females (P <0.001). Seropositivity rates for VZV were lower in younger cohorts; 21.3% of those born after 1974 were non-immune. Rates of hepatitis A non-immunity did not significantly differ between birth cohorts; testing revealed rates of seronegativity of 25% regardless of year of birth. Males were 1.48 times more likely to be seronegative for hepatitis B than females (P <0.001) and the highest hepatitis B seropositivity rates were seen in those born after 1982.
Discussion
Ensuring adequate vaccination prior to international travel is an important strategy to prevent individual morbidity and mortality from VPDs, and to protect communities both at home and abroad. This audit demonstrates that a significant proportion of pre-travel clinic attendees for whom immunity to specific VPDs cannot be definitively determined have serological results consistent with non-immunity to diseases that could be encountered during travel.
Measles is a highly transmissible disease with outbreak potential. National vaccination programs for measles are designed to ensure coverage rates that will provide herd immunity and therefore protect the community from outbreaks. This does not guarantee that every individual is immune, so some travellers may be at risk if they travel to an area with endemic or epidemic transmission. Although Australia has achieved measles elimination in 2014, infections in travellers are not uncommon 3 and outbreaks still occur following importation of disease by travellers. 4 Our data supports previous serological audits that have
shown that vaccine-induced immunity to measles often fails to exceed 90% at a population level. 4 Within certain high-risk groups, levels of immunity may be lower than this. 5 We have
shown that in Australia those born prior to 1966 have almost universal measles immunity, likely reflecting high rates of infection in the pre-vaccination era. We recommend that clinicians have a low threshold for assessment of seroprotection to measles in patients born after 1966 who cannot clearly demonstrate two previous doses of a measles containing vaccine or past infection. Knowledge of high-risk periods for non-immunity based on local vaccination practices is also required to guide testing. The overall lower rate of mumps immunity compared with measles is predominantly explained by lower rates of seropositivity in those born prior to 1966, confirming results of a recent serosurvey of healthcare workers performed in Melbourne, Australia. 4 This may suggest that natural immunity to mumps has some decay over time when compared to measles. Rates of positive rubella serology were significantly different between males and females, probably due to gender differences in the timing of introducing rubella vaccine in Australia with funded vaccination of women beginning in 1971 compared with 1989 for males.
Prior to the introduction of the varicella vaccine into the Australian childhood vaccination schedule in 2005, varicella infection was ubiquitous in Australia, with most adults immune due to previous exposure. A previous Australian serosurvey demonstrated an increase in seropositivity with age, with the highest force of infection in the 5-9 years age group and seropositive rates of 83% by ages 10-14 years. 6 Our audit demonstrated surprisingly low rates of VZV immunity in those born after 1982 (<50%), but this is likely due to the targeted testing performed and does not represent a population based estimate. It is possible that the availability of the varicella vaccine from 1999 and its introduction into the funded Australian schedule in 2005 has led to a reduction in the incidence of natural chickenpox infection in young children. Alternatively, epidemiological changes, such as the decline in average household size in Australia over this period may have reduced childhood exposure to VZV. 7 Hepatitis A represents a risk to unvaccinated travellers going from areas of low prevalence to areas of higher prevalence. While a past history of infection or a history of a full course of vaccination (two doses of monovalent vaccine or three doses of a hepatitis A/B combination vaccine) provides long-term immunity, travellers are often unable to provide a clear history or documentation of vaccination or exposure. Prior infection is more likely in individuals born before 1950 or in those who spent their childhood in endemic countries, but infection is often mild or asymptomatic meaning history is not a reliable indicator of immunity. While country of birth was not specifically documented in this audit, most travellers attending the clinic are Australian-born and therefore the high rates of non-immunity are unsurprising as the vaccine is not included in Australia's routine childhood schedule. Our data support the use of routine hepatitis A serology in all patients without a clear history of appropriate vaccination.
We have demonstrated that serological evidence of hepatitis B immunity is often lacking in travellers. This is likely to reflect a lack of universal vaccination in Australia until the year 2000, with vaccination efforts prior to this focussing on high-risk groups. While previous travel clinic studies have demonstrated high rates of previous or current infection in travellers, the low rate of overseas-born patients among attendees of our clinic makes this an unlikely explanation for the low rates of immunity (although we acknowledge that testing for previous or current infection with hepatitis B was not performed). 8 Data from a recent study suggest that up to 50% of short-term travellers have a potential hepatitis B risk exposure during their trip. 9 In addition, countries with high hepatitis B prevalence are becoming increasing popular destinations from Australian travellers, with 7 out of the top 10 destinations for Australian travellers falling into this category. 10 We found a statistical difference in seronegativity rates between males and females, which is difficult to explain without access to further epidemiological data such as profession and risk behaviours. Our data support the use of serology to identify those at risk and to consider vaccination prior to travel. In this study, we investigated immune responses to VPDs where serology is well established to provide evidence of adequate immunity. In contrast, serology has no role in establishing adequate immunity against influenza, typhoid and meningococcal disease, and its role in establishing seroimmunity to other VPDs associated with travel such as polio and tetanus is limited to special circumstances. If there is no adequate record of vaccination to these VPDs, vaccination should be offered where indicated and the patient should be provided with written documentation.
We recognize that our study has significant limitations. Firstly, serology was ordered based on a subjective assessment by an individual clinician rather than following a pre-specified protocol, which likely biases the data towards finding higher rates of seronegative patients. However, our results reflect a real-world, targeted testing approach and have demonstrated clinical utility in this context. Secondly, we have assumed that all patients below the serological cut-off were non-immune. This assumption may be incorrect, as immune memory following adequate vaccination may continue in the absence of persistent high serological titres. However, this cut-off has practical significance in terms of who should be offered (re)vaccination. Thirdly, this study is based on Australian recommendations and vaccination practices. While our recommendations to be guided by patient history and vaccine documentation are generalizable and in line with strategies recommended in other studies, 11 local knowledge of historical vaccination programs is required to identify those most at risk for non-immunity. Finally, we have not assessed the cost-effectiveness and safety of performing serology to guide vaccination. However, small retrospective studies have demonstrated that pre-vaccination screening can be cost effective in travellers with an unclear history of past disease exposure.
12,13
Overall we have provided evidence that screening for immunity to MMR, VZV, hepatitis A and B prior to travel reveals significant levels of non-immunity in those with an unclear history of vaccination or disease. We recommend that travel health clinicians assess patients' vaccination and infection histories, and strongly consider serology or vaccination in any situation where there is doubt about immunity in order to protect the traveller and to prevent importation of disease into destination or home communities.
